ReviewAustralian prescriber2019
Meningococcal vaccines in Australia: a 2019 update.
Review in Australian prescriber, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Genomic Surveillance of Invasive Meningococcal Disease During a National MenW Outbreak in Australia, 2017-2018.Open forum infectious diseases · 2024Article
- The genomic epidemiology ofThe Lancet regional health. Western Pacific · 2024Article
- Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review.Infectious diseases and therapy · 2023Review
- Real-world impact and effectiveness of MenACWY-TT.Human vaccines & immunotherapeutics · 2023Review
- Impact of COVID-19 Containment Strategies and Meningococcal Conjugate ACWY Vaccination on Meningococcal Carriage in Adolescents.The Pediatric infectious disease journal · 2022Article
- Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries.Human vaccines & immunotherapeutics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
invasive meningococcal disease is a rare but serious infection caused by neisseria meningitidisSEROGROUP B WAS THE PREDOMINANT SEROGROUP CAUSING INVASIVE MENINGOCOCCAL DISEASE IN AUSTRALIA UNTIL 2015 SEROGROUP W DISEASE HAS INCREASED SUBSTANTIALLY SINCE 2014 AND IN 2017 SEROGROUPS B AND W CAUSED SIMILAR NUMBERS OF INVASIVE DISEASE CASES: VACCINES AGAINST SEROGROUPS A C W Y AND B ARE AVAILABLE FOR ANYONE WHO WISHES TO REDUCE THE RISK OF MENINGOCOCCAL DISEASE: VACCINATION IS STRONGLY RECOMMENDED FOR PEOPLE IN HIGH-RISK AGE OR POPULATION GROUPS THESE ARE CHILDREN UNDER 2 YEARS 15–19 YEAR OLDS ABORIGINAL AND TORRES STRAIT ISLANDER CHILDREN AND PEOPLE WITH MEDICAL OCCUPATIONAL BEHAVIOURAL OR TRAVEL-RELATED RISK FACTORS FOR INVASIVE MENINGOCOCCAL DISEASE: MENINGOCOCCAL ACWY VACCINE IS FUNDED UNDER THE NATIONAL IMMUNISATION PROGRAM FOR BABIES AGED 12 MONTHS SINCE APRIL 2019 IT HAS BEEN FUNDED FOR YEAR 10 STUDENTS THROUGH A SCHOOL PROGRAM THERE ARE ADDITIONAL STATE AND TERRITORY-BASED PROGRAMS FOR BOTH MENINGOCOCCAL ACWY AND MENINGOCOCCAL B VACCINES:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.